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Chapter 8 Drug expectations and drug choices of hospital 
physicians1 
Objectives - To assess whether differences in drug choices of hospital physicians are 
related to differences in the underlying decision-making process. 
Design - A survey study was conducted addressing drug choices in six therapeutic fields 
with existing interprescriber variations; prescribers and non-prescribers of drugs of 
which the merits were not sufficiently proven (i.e. the 'target drugs') were compared. 
Setting - A 1000-bed university hospital in The Netherlands. 
Subjects - All 85 hospital physicians working in specialties involving one of the 
selected fields were asked to participate; 72 physicians completed the interviews. 
Main outcome measures - Comparisons were made regarding three elements of the 
decision-making process: (1) the physicians' expectations of the target drugs and 
frequently used alternatives, (2) the weights attached to the principal treatment aspects, 
and (3) the extent to which their actual choice is based on these expectations and 
weights. 
Results - In three fields, i.e. anti-emetics, vasodilators, and platelet inhibitors, the 
prescribers of the less desirable target drugs had higher expectations of these drugs in 
comparison to the non-prescribers. In the other therapeutic fields, choosing target drugs 
was related either to attaching less importance to side effects and costs, or to attaching 
less importance to reports from clinical trials. Twenty of the 46 treatment choices of 
the prescribers of target drugs could not be predicted from their expressed views as 
opposed to 5 of the 36 choices of the non-prescribers (P < 0.05). 
Conclusions - Choosing less desirable drugs is not always related to having too high 
expectations of the drug. Assigning a different weight to certain aspects of the drug and 
resorting to decision strategies that do not include the weighing of all pros and cons 
provide alternative explanations for such treatment choices. 
' This chapter has been published in the J Internal Medicine 1993;234:155-163, Denig P, Haaijer- 
Ruskamp FM, Wesseling H, Versluis A, Drug expectations and drug choices of hospital physicians. 
Permission for reprint granted by Blackwell Scientific Publications. 
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8.1 Introduction 
In standard patients, there is no real need to choose drugs whose value is not 
sufficiently proven, or drugs that have no significant advantage over older drugs. Also, 
there should be a limited need to prescribe drugs that are warranted only in exceptional 
cases. However, some physicians do prescribe such drugs for standard patients, whereas 
others do not. Understanding the reasons underlying such variations in prescribing can 
help us to develop efficient educational approaches to optimize the quality of 
prescribing. 
Various researchers have tried to describe drug-choice and prescribing behaviour 
focusing on the reasoning process of the prescriber [1,2]. Several studies support the 
view that physicians have certain positive as well as negative 'expectations' regarding 
the treatments on which they base their choice. Expectations that have been found to 
influence the drug choice concern biomedical aspects, e.g., efficacy, side effects and 
convenience of use, as well as questions of costs, and other aspects, e.g., anticipated 
approval of colleagues, patient wishes and personal experiences 13-71. These 
expectations can differ between individual physicians leading to variations in drug 
choice and prescribing behaviour. Also, the importance or so-called 'weight' individual 
physicians attach to each aspect varies and can influence the final choice. For example, 
if a certain physician believes that a high degree of efficacy and good personal 
experience with a drug are more important than low costs or few documented side 
effects, the latter aspects might have little influence on his choice. Whereas another 
physician might put more weight on the costs, and, consequently, choose a different 
treatment. 
Other studies have shown that physicians also choose by using simple decision rules 
[8,9]. Such rules indicate that not all pros and cons of different treatments are 
evaluated. This might result in drug choices that are not in agreement with what one 
would have anticipated from the physician's own expectations regarding the different 
treatments. 
Thus, the prescribing quality is not only influenced by what a physicians expects of 
a drug treatment, but also by the extent to which the choice is based on these 
expectations. The present study investigates whether differences in drug choices can be 
explained by differences in the underlying decision-making process. This question was 
addressed in a survey study among physicians working in a university hospital in The 
Netherlands, which at the time of the study did not have a restrictive drug formulary. 
8.2 Selection of target drugs 
A comparison was made between physicians who differed in their choice of drugs. Six 
therapeutic fields were selected in which variation existed in the treatments used by the 
physicians within the hospital. The fields chosen were: [I] anti-emetics for patients 
undergoing chemotherapy, [2] narcotic analgesics for severe pain after surgery, [3] 
vasodilators for haemodynarnically unstable patients, [4] platelet inhibitors for patients 
with a shunt or bypass, [5] antihypertensive drugs for patients with renal problems, and 
[6] antibiotics for respiratory infections of unknown origin. In each field, certain drugs 
were in use that were not regarded as drugs of first choice for standard patients (though 
they might be appropriate for certain individual patients). These drugs were the target 
drugs in this study. Physicians who chose to prescribe the target drugs for a standard 
patient (the 'prescribers') were compared to physicians who did not choose those drugs 
(the 'non-prescribers'). 
Four of the target drugs were drugs for which there is no real need, because they 
have no significant advantage over 'older' and more extensively tested alternatives 
(alizapride instead of metoclopramide, and sufentanyl instead of fentanyl), or drugs 
whose value is not (yet) sufficiently proven (ketanserine for haemodynamically unstable 
patients, and dipyridamole for patients with a bypass or shunt). These were the so- 
called 'no-need' drugs. The two other target dnlgs were drugs that are only warranted 
in exceptional cases (clonidine for hypertensive patients, and imipenem/cilastatin for 
respiratory infections of unknown origin). These were called the 'limited-need' drugs. 
An extensive description of the choice of the target drugs has been published elsewhere 
[lo]. Table 8.1 presents an overview of the target drugs and their most frequently used 
alternatives in each of the selected therapeutic fields. 
Table 8.1 Target drugs, alternative treatments, and numbers of physicians per therapeutic 
field 
field target drug frequently used prescribers non-prescribers total 
altentanntanve of target of target 
drugs drugs 





















metoclopramide 14 (12) 4 (4) 18 
fentanyl 4 (4) 8 (1) 12 
nitroglycerin 4 (4) 4 (3) 8 
acetosal 9 (7) 11 (9) 20 
betablocker 10 (9) 11 (8) 2 1 
(metoprolol,atenolol) 
cefuroxim 11 (9) 4 (3) 15 
+ tobramycin 
(Nx) = the number of physicians who provided detailed expectations as to the target drug in 
question 
8.3 Study population 
All 85 physicians working in the specialties that involve patients in one of the selected 
therapeutic fields were asked to participate in the study. Seventy-two physicians 
completed the interviews (response rate 72/85=85%). The average age of the 
responding physicians was 38 years (ranging from 29 to 52), and 65 of them were men. 
Of the respondents, 49 had been in practice as a specialist between 1 and 26 years 
(average 8 f 6 years), and 23 were specialist trainees. Only 11 physicians had received 
their complete training in another hospital; the others were at least in part trained at the 
hospital studied. 
All 72 physicians were interviewed r e m g  their drug choices in one of the six 
selected fields depending on their specialty. TabIe 8.2 shows the number of physicians 
and the therapeutic fields per specialty. The specialists are classified according to the 
separate departments in the hospital. The average frequency of patient contacts in those 
selected fields would be at least one patient per physician per day. Physicians familiar 
with more than one of the six selected fields, i.e. cardiologists, nephrologists, 
haematologists, internists, and one surgeon who frequently worked at the intensive care 
unit, were asked to be interviewed regarding a second therapeutic field, because 
otherwise the number of respondents in each field would be very small (see also table 
8.2). The interviews took from 1 to 1% hour. 
Table 8.2 Numbers of physicians, and selected therapeutic fields per specialty 
specialty total nwnber selected number of physicians 






























Total 72 94' 
* physicians from internal medicine were arbitrarily allocated to the therapeutic fields 
22 physicians were interviewed regarding a second therapeutic field 
In order to eliminate sources of inter-hospital variation, the present study was limited 
to physicians who were all working at the same hospital. As a consequence, the number 
of study subjects was limited. In most therapeutic fields, no more than 20 physicians 
were involved in the actual treatment of patients. Therefore, despite the high response 
rate, the subgroups between which comparisons have been made were small, and as a 
result the power to detect small differences between the groups was low. 
There were no signihmt differences between prescribers and non-prescribers of the 
target drugs in each thempeatic field in terms of their age, sex, number of years in 
practice, the hospital at which they had received their training, or the frequency of 
patient contacts in the selected theI;lpeutic fields. Only the prescribers of the platelet 
inhibitor target drug (dipyridamole) were more fully registered specialists (only one of 
the nine prescribers was a specialist trainee, whereas six of the 11 non-prescribers 
were; P < 0.05), but taking all strata together, there were no significant differences 
between the specialist trainees and the fully registered specialists with regard to their 
prescribing of the target drugs. Some small and inconsistent differences were found 
with regard to the information sources used by the physicians. Participation in clinical 
trials seemed to be a relevant factor in two of the fields. The anti-emetic drug alizapride 
had been tested by four of the oncologists in the course of a comparative study between 
alizapride and metoclaprarnide. Their unanimous conclusion was that -pride was no 
better than metoclopramide, and in consequence they were all non-prescribers of 
alizapride (comparison of prescribers and non-prescribers regarding participation in 
clinical trial; P < 0.05). Three of the four prescribers of the vasodilator target drug 
ketanserine had been involved in giving test courses of this drug prior to its registration 
in The Netherlands. These tests, however, did not include comparisons of dierent 
ueatments, nor was any kind of scientific evaluation reported (comparison of 
prescribers and non-prescribers regarding participation in test courses; P < 0.05). 
8.4 Methods 
The physicians were interviewed using general case descriptions referring to a standard 
patient with no complications. Although there is no clear consensus as to the validity 
of written case simulations for measuring actual (prescribing) behaviour, such case 
descriptions seem to provide an effective research instrument for eliciting expectations 
and clarifying the decision-making p m s  [ll]. A typical case description would read 
as follows: 
Consider the situation of a patient who received a @pass; there are no complica- 
tions and no ahnormal conditions. Would you prescribe any treatment to prevent 
blood coag&tion? If so, which treament(s) would you prescribe? 
This question provides information about the dmgs the physicians normally consider to 
prescribe for a staodard case of the indication mentioned ('prescribing intention'). The 
answer to this question was used to identify prescribers of the target drugs. Whenever 
we speak of the 'prescribers' of a specific target drug, we have assumed that the 
physicians who stated that they would prescribe such a drug for a certain patient group 
in general, will actualIy prescribe the drug for some of theu existing patients. After 
having answered the question regarding the treatment, the physicians wen? asked to 
estimate the expeded pros, cons, and overall utility of all drugs routinely in use for the 
given indication, klud'ig the target drugs. These estimates can be seen as their 
expecCutiom (@ regarding the principal aspects of each treatment. The following aspects 
were included. 
1. BiomedicaI and economic aspects, i.e. estimates of efficacy, rate of onset of the 
desired effect, side effects, frequency of dosage, costs, and -for the antibiotics- the 
risk of developing resistance. 
2. Social aspects, i.e. anticipated approval by professional colleagues, and patient 
wishes as to the use of a specific drug. 
3. Experiences, i.e. their personal experience, the experience believed to exist 
generally with the drug in question, and the experience reported by others in clinical 
trials. 
4. Overall utility, i.e. an estimate of the utility of each drug as a whole for the 
presented case description. 
The (translated) questions as well as the scales used are presented in table 8.3. 
Table 8.3 Questions regarding the expectations of physicians 
Can you estimate the percentage of patients such as those described' for whom treatment A (B, C & D) 
is sufficiently effective according to your own opinion? ('sufficiently' indicates that you are satisfied with 
the @cacy of the treatment) (scale 0-100%) 
Which side effects are experienced by patients such as those described who are treated with A (B, C & 
D)? Can you estimate the percentage of these patients? (scale 0-100%) 
Do you consider the average rate of onset of the effect of treatment A (B, C & D) for patients such as 
those described as slow, intermediate, or fast? 
Do you consider the frequency of dosage, respectively the routes of administration of treatment A (B, 
C & D) for patients such as those described as constituting a serious problem, a minor problem, or no 
problem? 
Do you consider the antibiotic resistance of treatment A (B, C & D) for patients such as those described 
as constituting a serious problem, a minor problem, or no problem? 
Can you estimate the average costs per day of treatment A (B, C & D) for patients such as those 
described? 
How do you think your colleagues (the pharmacists, the nurses, and the family physicians) think about 
treatment A (B, C & D) for patients such as those described? Express their opinion on a 10-point scale, 
where. 1 is extremely negative and 10 is extremely positive. 
How do you think the patients think about treatment A (B, C & D)? Express their opinion on a 10-point 
scale, where 1 is extremely negative and 10 is extremely positive. 
Can you express your personal experience, the amount of experience in general, and the experience 
reported in clinical trials, respectively, with treatment A (B, C & D) for patients such as those described 
on a 10-point scale, where 1 is extremely negative and 10 is extremely positive? 
Can you give an overall judgement of treatment A (B, C & D) for patients such as those described on 
a scale from 1 (treatment is worthless) to 10 (treatment is extremely good)? 
* Physicians were interviewed using general case descriptions referring to a standard patient with no 
complications. 
Some physicians chose not to evaluate all drug treatments that were presented to them 
in detail, because they were either not able to express their expectations in exact figures 
or were not familiar with a particular drug. The number of physicians that evaluated 
the selected target drugs in each field is indicated in table 8.1 as Nx. 
The physicians were asked to express the weight (W) they attached to each of the 
previously mentioned aspects when choosing a drug for that particular patient. Referring 
to the general case description, the question was: 'How important is the eflcacy (rare 
of onset, side eflects, etc.) of a treatment to you when you choose a treatment for this 
kind of patient?' The weights were rated directly on scales from 0 ('aspect is not 
impoltant at all') to 10 ('aspect is extremely important'). 
To establish whether the drug choices of the physician could be seen as based on 
their own expectations, we sought to predict their preferred treatment by an analytical 
decision model (see [7] for a detailed description of such a model). Using a linear 
additive model, the total 'expected values' were calculated for each therapy and each 
physician; all expectations relating to treatment aspects were recoded on scales from 0 
to 100 and then weighted according to the weights assigned to them by the physician 
concerned. These weighted scores for each therapy were added together and the total 
score was regarded as the expected value (EV) of a drug. Mathematically this expected 
value can be described as: EVj = E Wi . Eii, where E y  is the expected value of 
treatment j, W, is the weight assigned to aspect i, and Eij is the expectation of aspect i 
of treatment j. The drug with the highest expected value is the model's prediction of the 
physician's first-choice drug. For each physician, this prediction was compared to the 
actual treatment choice as indicated by that physician in answer to the written case 
description. If a physician disregards aspects that helshe says are important for hislher 
treatment choice, the agreement between the model's prediction and the actual choice 
will be low. 
8.5 Data analysis 
The expectations (Eli) expressed by the prescribers and the non-prescribers regarding 
the target drug were compared. Furthermore, possible differences between the 
expectations regarding the target drugs and the alternatives were analysed within both 
groups. Secondly, the weights (WJ attached to the treatment aspects by the two groups 
were compared. Thirdly, both groups were compared regarding the agreement of their 
actual drug choices with the expected values (EVJ of the treatments. 
The ~ i g ~ c a n c e  of differences found between groups was tested using Students' t- 
tests for normally distributed data, Mann-Whitney U-tests for skewed distribution of 
data and ordinal-level data, and chi-squared tests for data at the nominal level, using 
a significance level of a=0.05. The significance of differences found within a group 
were tested using either paired t-tests, Wilcoxon tests for skewed distribution of data 
with Bonferroni adjustments made for multiple comparisons, and sign tests for data at 
the ordinal level. 
8.6 Results 
Expectations (EJ 
In the field of narcotic analgesics, differences in expectations could not be tested 
because only one non-prescriber had expressed expectations of the target drug (see also 
table 8.1). In the fields of antihypertensives and antibiotics, no significant differences 
were found in the expectations of prescribers and non-prescribers. In other words, 
physicians who chose to prescribe clonidine or imipenemlcilastatin did not have a 
higher opinion of these drugs than their colleagues did. In the other three therapeutic 
fields, expectations differentiating between the prescribers and non-prescribers of the 
target drugs were limited to the efficacy, personal experience, and overall utility of the 
drugs (table 8.4). Significant differences were encountered with regard to the anti- 
emetics, and to a smaller extent with regard to vasodilators and platelet inhibitors. Not 
surprisingly, the prescribers of the target drugs had significantly more positive 
expectations regarding the target drugs or more negative expectations regarding the 
alternatives. In none of the other biomedical or economic aspects did the expectations 
differ, nor were any significant differences found in the social aspects of the drugs, i.e. 
the perceived pmfessional approval and the perceived patients' wishes. 
Table 8.4 Differences in expectations between prescribers (P) and non-prescribers (n-P) of 
alizapride, ketanserine, and dipyridamole (efficacy in percentage, own experience 
















64 (20) 42 (39) 
7.OV(1 -6) 5.571 .O) 
7.3r(1 .4) S.S'(O.6) 
ketmerine 
87 (18) 70 (8) 
8.3 (0.6) 5.0 (1.4) 
8.0' (0.8) 5.W(1 .O) 
dipyridamole + acetosal 
67 (13) 71 (13) 
7.7 (0.6) 6.2 (1.6) 




54 ( 1  8) 42 (39) 
6.6*(1.1) 5.8 (1.0) 
6.T(l. I) 5.5 (0.6) 
nitroglycerin 
80 (3 78 (15) 
8.0 (0.0) 8.0 (0.8) 
8.0 (0.8) 8.08(0.8) 
acetosal 
61 (16) 70 (15) 
6.3 (1 -1) 7.8 (1.2) 
6.(Y(l .O) 7.4'(0.5) 
significant difference between the expectations regarding the target drug and its alternative 
within one group of physicians (P < 0.01) 
' significant difference between prescribers and non-prescribers (P < 0.05) 
Weights (W3 
Weights assigned to the biomedical and economic aspects were signif~cantly different 
for the prescribers and non-prescribers in two of the six therapeutic fields (table 8.5). 
The first field was that of the narcotic analgesics, where prescribers of sufentanyl 
assigned significantly more weight to the rate of onset of effect than did the non- 
prescribers. In the second field, concerning the antibiotic treatment, the prescribers of 
imipenem/c&tatin attached sig
nifi
cantly less weight to side effects and costs compared 
with the non-prescribers. 
Turning to the weight attached to the non-medical aspects, in two of the therapeutic 
fields, namely concerning narcotic analgesics and antihypertensives, the weight attached 
to reports from clinical triaIs was significantly lower for the prescribers in comparison 
to the non-prescribers (table 8.5). Furthennore, in all but one field the prescribers more 
often valued their personal experiences as more important than reports from clinical 
trials, a finding contrasting to that within the group of the non-prescribers. Only when 
it came to the evaluation of a prophylactic therapy, e.g. platelet inhibition for patients 
with a shunt or bypass, did a majority of the physicians in both groups attach more 
weight to reports from clinical trials than to personal experience. In the other five 
fields, the prescribers valued personal experiences as more important 16 times, reports 
from clinical trials only five times, and 22 valued personal experience and clinical trial 
results equally (sign test, P < 0.05). The non-prescribers valued personal experiences 
as more important 11 times, as less important nine times, and equally important to 
clinical trials 11 times (sign test, P = 0.8). 
Table 8.5 Differences in weights between prescribers (P) and non-prescribers (n-P) of the 
target drugs (scale 0-10, standard deviations in between brackets) 
- - - - - - - 
Biomedical and economic aspects Other aspects 
efficacy rate of side dosage cost own clin. 
onset effects frequency exper. trials 
Anti-emetics 
P 9.5(1.2) 8.1(2.7) 8.2(2.6) 5.6(3.0) 3.1(3.0) 8.4(0.8) 
n-P lO.O(O.0) 5.6(1.9) g.S(O.6) 4.3(1.7) 2.0(1.8) lO.O(O.0) 
Narcotic analgesics 
P 9.8(0.5) 9.8*(0.5) 7.3(3.1) g.O(l.4) 2.8(4.3) g.O(l.2) 
n-P 9.4(0.8) 7.9*(0.7) g.O(l.6) 6.10.7) 6.7(1.7) 8.3(1.1) 
Vasodilators 
P 9.8(0.5) 9.3(1.0) 7.5(1.3) 5.0(4.4) 2.3(2.9) 9.3(1.0) 
n-P lO.O(O.0) 9.5(1.0) 8.8(1.3) 2.3(4.0) 4.3(2.4) g.S(O.6) 
Platelet inhibitors 
P 9.9 (0.4) - 8.3 (1.0) 7.1 (2.2) 4.8 (2.3) 7.9 (1.9) 
n-P 9.4(1.1) - 8.2 (1.5) 6.0 (1.4) 3.4 (2.6) 7.9 (1.6) 
Antihypertensives 
P 9.4(0.8) 5.6(2.8) 7.90.2) 7.3(1.3) 5.6(2.6) 7.6(2.1) 
n-P 9.3(1.1) 5.5(2.3) 9.4(0.7) 8.2(1.6) 6.3(2.3) 8.3(1.2) 
Antibiotics 
P 9.9(0.3) 8.6(1.7) 6.8*(2.1) 4.6(3.1) 3.7*(1.9) g.l(l.8) 
n-P 9.5(0.6) 8.7(1.5) 8.8(1.0) 5.3(0.5) 6.5(1.3) 8.5(1.0) 
significant difference between prescribers and non-prescribers of the target drug (P < 0.05) 
Agreement of choice with erpecrananons and weights (Ey  = E W, . E& 
The m e n t  choices of the prescribers of target drugs were less in agreement with 
what one would have anticipated f m  their previously expressed expectations and 
weights, compand to the choices of the non-prescribers (table 8.6). In the group of 
prescribers, 26 choices were predicted correctly and 20 incorrectly, whereas among the 
non-prescribers 31 choices were predicted correctly and only five incorrectly 
(chP=8.34, P < 0.004). 
Table 8.6 Predictions of treatment choices using an analytical decision model based on 
expected values EVj = C Wi . Eij (numbers of correct and incorrect predictions; 
physicians who evaluated only one treatment were excluded) 
correct incorrect 
Anti-emetics prescribers 8 4 
non-prescribers 3 0 
Narcotic analgesics prescribers 2 2 
non-prescribers 4 1 
Vasodilators prescribers 3 1 
non-prescribers 4 0 
Platelet inhibitors prescribers 4 4 
non-prescribers 9 0 
Antihypertensives prescribers 4 5 
non-prescribers 7 4 
Antibiotics prescribers 5 4 
non-prescribers 4 0 
Total prescribers 26 20 
non-prescribers 3 1 5# 
' significant difference between prescribers and non-prescribers of the target drugs, P < 0.05 
8.7 Discussion and conclusions 
In this study, the question was addressed as to what extent differences in the drug 
choices of hospital physicians may be explained by differences in their expectations, in 
the weight they attach to the various aspects of the treatments, or in the extent to which 
their choice is based on these expectations and weights. In other words, the focus of 
this study is the decision-making process underlying the drug choice of a hospital 
physician. There are many factors that affect this process. Education, professional and 
commercial information, participation in clinical trials, and personal experience may all 
influence the expectations and weights used by the physicians [12]. No consistent 
relationship, however, was found between most of these background variables and the 
prescribing of the 'no-need' or 'limited-need' target drugs. One aspect of importance 
seemed to be participation in a clinical trial, but this may exert both positive and 
negative influences. If the conclusion of a trial is clearly not in favour of a newly tested 
drug, as was the case for alizapride, it will probably not lead to its use. If there is not 
an explicit conclusion, as was the case for ketanserine, participation in trials seemed to 
lead more frequently to the prescription of that drug. This effect of clinical trials of 
stimulating the adoption of drugs whose value is not (yet) sufficiently proven has also 
been observed in other cases [13]. The influence of participation in clinical trials might 
be mediated through the overall expectations the physician has regarding the drug, as 
these expectations regarding both target drugs alizapride and ketanserine were 
significantly different for the prescribers of these drugs when compared to the non- 
prescribers. 
As was mentioned previously, the number of subjects in this study was small, which 
limits the power to detect small differences. When possible, the findings from the 
various therapeutic fields have been combined and discussed as a whole. Differences 
in expectations could only distinguish between prescribers and non-prescribers of three 
of the four 'no-need' drugs (i.e. alizapride, ketanserine, and dipyridamole). The 
prescribers of those drugs had better experiences with, and higher expectations of the 
efficacy and overall utility of these drugs than did their colleagues. Choosing a 'limited- 
need' drug (i.e. imipeneml cilastatin or clonidine) for a standard case is apparently not 
related to having too high an expectation of the drug. It seems that assigning a different 
weight to certain aspects of the treatment provides a better explanation for these drug 
choices. Physicians who chose imipenem/cilastatin (a new and expensive antibiotic) 
attached relatively less importance to side effects and costs. Physicians who chose 
clonidine valued findings from clinical trials as less important. 
With the exception of dipyridamole, prescribers of the target drugs more often 
valued their personal experience as more important than reports from clinical trials. 
This supports the finding of Schwartz et al. that an important reason to prescribe 
'nonscientific' drugs was the physician's disbelief of the scientific information and 
favourable personal experience with the drugs [14]. The exception of dipyridamole can 
be explained by the fact that this is a prophylactic therapy whose effects are much more 
difficult to evaluate by personal experience. 
Finally, it appeared that the drug choices of physicians who chose the target drugs 
were often not in agreement with their previously expressed views on these drugs. Such 
a discrepancy between what physicians do and what they think they do, has been 
described in other studies as well [15,16]. As this discrepancy was larger for the 
prescribers of 'no-need' and 'limited-need' drugs, it seems that some of these choices 
are the result of decision strategies that do not include the weighing of all pros and cons 
of the various treatments. 
In conclusion, choosing less desirable drugs is not always the result of having 
incorrect expectations regarding these drugs. One reason why some physicians choose 
such drugs seems to be related to the weight attached to certain aspects, such as the 
relatively high weight they attach to personal experience. Moreover, physicians do not 
always act according to their expectations when actually choosing a drug treatment. 
8.8 Implications for education 
Phannacotherapeutic education of physicians during their university training, as well 
as during postgraduate training, traditionally addresses knowledge about biomedical and 
-more recently- economic aspects of the treatments. Our results regarding the 
discrepancy between expectations and actual drug choices suggest that in order to ensure 
optimal drug choices in practice this approach is not sufficient. (Future) physicians 
should also learn to utilize their biomedical knowledge and expectations in practice. At 
the moment, the World Health Organisation is developing pharmacotherapeutic training 
programmes for medical students which specifically attend to this problem [17]. These 
programmes adopt a problem-solving approach and focus on skills in applying 
knowledge. In postgraduate education, it seems important that physicians are confronted 
with the discrepancies between what they do and what they think they do. The weights 
physicians apparently attach to certain treatment aspects can be elicited from their actual 
treatment choices. JiQerirnents indicate that such individual feedback regarding the 
decision-making process, i.e. showing physicians what they actually do in practice, 
could be an effective educational tool 118-201. Furthermore, postgraduate education 
pmgrammes should allow for a discussion of both the personal experience of 
physicians, as well as the weight attached to those experiences. As the prescribers of 
some of the less desirable drugs value reports from clinical trials as relatively 
unimportant, prescribing will not easily be changed by showing fmdings from the 
literature that differ from the personal experiences of these physicians. 
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